Reply  by Di Marco, John P
464 LETTERS TO THE EDITOR JACC Vol. 8. No.2
August 1986:462-4
References
I. Watt AH, Bernard MS, Webster J. Passani SL, Stephens MR, Routledge PA.
Intravenous adenosine in the treatment of supraventricular tachycardia: a dose-
ranging study and interaction with dipyridamole. Br J Clin Pharmacol (in press).
2. Di Marco JP, Sellers TO. Lerman BB. Greenberg ML. Berne RM. Belardinelli
L Diagnostic and therapeutic use of adenosine in patients with supraventricular
tachyarrhythmias, J Am Coli Cardiol 1985;6:417-25.
3. Watt AH. Routledge PA. Adenosine stimulates respiration in man. Br J Clin
Pharmacol 1985;20:503-6.
4. Cushley MJ. Tatterstield AE. Holgate ST. Inhaled adenosine and guanosine on
airway resistance in normal and asthmatic human subjects. Br J Clin Pharmacol
1983;15:161-5.
Reply
We agree that transient dyspnea is common after injection of doses
of adenosine sufficient to produce change in sinus rate at rest.
However, in comparison studies, we (1) have shown that the dos-
age required to terminate paroxysmal supraventricular tachycardia
in the same patient is usually lower and thus the sensation of
dyspnea is much less common.
The effects of adenosine on respiration are still incompletely
understood. Some authors (2) have concluded that adenosine is a
central respiratory depressant rather than a stimulant as proposed
by Watt. In our experience, most patients with severe asthma are
receivmg a methylxanthine. Because methylxanthines in thera-
peutic doses block the electrophysiologic effects of adenosine, we
have not treated any such patients. Two of our patients had a
history of mild asthma that did not require long-term prophylactic
therapy; neither reported any unusual side effects from adenosine.
Finally, the unusually rapid elimination of adenosine after injection
is due to rapid cellular uptake by a mechanism blocked by dipyr-
idamole. In our study we excluded patients receiving this agent
because we anticipated that markedly lower dosage requirements
would be observed. Because alternative forms of therapy are usu-
ally available, one might question whether adenosine should be
the drug of choice in patients receiving dipyridamole.
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